Select Country

 
877-783-6728 (877-StemSave)

StemSave Blog

Big Pharma Wades into Regenerative Medicine

Posted by maxi@stemsave.com on Dec 15, 2016 4:00:00 PM

A $225m investment from pharmaceutical giant Bayer catapults BlueRock Therapeutics onto the stem cell therapy stage. BlueRock will initially focus on cardiovascular and neurological treatments.  A team led by Dr. Michael Laflamme and Dr. Gordon Keller will concentrate on regenerating heart muscle for patients who have suffered a heart attack, whilst a team led by Dr. Lorenz Studer and Dr. Viviane Tabar will concentrate on restoring dopamine-producing cells in patients with Parkinson's disease .

Read More

Topics: parkinsons disease, Heart Attack, stem cell therapy, Bayer, BlueRock Therapeutics, cardiovascular treatments, neurological treatments

AAOMS

AAOMS - American Association of Oral and Maxillofacial Surgeons

 

As the industry leader, StemSave is the only stem cell banking service to be designated as an ASI approved program.

Subscribe to Email Updates

Join our Newsletter

Posts by Topic

see all